Alteogen Partners with Biogen for Exclusive Licensing Deal Worth Up to 867.5 Billion Won

Alteogen has signed an exclusive licensing deal with Biogen worth up to 867.5 billion won for subcutaneous biologics using its Hybrozyme platform. The deal includes an upfront payment of 30 billion won and potential milestone payments of up to 822.6 billion won. Alteogen will receive royalties based on net sales after product launches, with the agreement contingent on successful clinical trials and regulatory approvals.